Pharmacology and physiology of gastrointestinal enteroendocrine cells
Authors:
Open Access
- 7 July 2015
- journal article
- review article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 3 (4) , e00155
Abstract
Gastrointestinal (GI) polypeptides are secreted from enteroendocrine cells (EECs). Recent technical advances and the identification of endogenous and synthetic ligands have enabled exploration of the pharmacology and physiology of EECs. Enteroendocrine signaling pathways stimulating hormone secretion involve multiple nutrient transporters and G protein‐coupled receptors (GPCRs), which are activated simultaneously under prevailing nutrient conditions in the intestine following a meal. The majority of studies investigate hormone secretion from EECs in response to single ligands and although the mechanisms behind how individual signaling pathways generate a hormonal output have been well characterized, our understanding of how these signaling pathways converge to generate a single hormone secretory response is still in its infancy. However, a picture is beginning to emerge of how nutrients and full, partial, or allosteric GPCR ligands differentially regulate the enteroendocrine system and its interaction with the enteric and central nervous system. So far, activation of multiple pathways underlies drug discovery efforts to harness the therapeutic potential of the enteroendocrine system to mimic the phenotypic changes observed in patients who have undergone Roux‐en‐Y gastric surgery. Typically obese patients exhibit ~30% weight loss and greater than 80% of obese diabetics show remission of diabetes. Targeting combinations of enteroendocrine signaling pathways that work synergistically may manifest with significant, differentiated EEC secretory efficacy. Furthermore, allosteric modulators with their increased selectivity, self‐limiting activity, and structural novelty may translate into more promising enteroendocrine drugs. Together with the potential to bias enteroendocrine GPCR signaling and/or to activate multiple divergent signaling pathways highlights the considerable range of therapeutic possibilities available. Here, we review the pharmacology and physiology of the EEC system.Keywords
This publication has 220 references indexed in Scilit:
- Oligopeptides stimulate glucagon-like peptide-1 secretion in mice through proton-coupled uptake and the calcium-sensing receptorDiabetologia, 2013
- Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cellsDiabetologia, 2013
- Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodentsDiabetologia, 2012
- Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretionDiabetologia, 2012
- β-arrestin-mediated receptor trafficking and signal transductionTrends in Pharmacological Sciences, 2011
- Peptide YY Is Critical for Acylethanolamine Receptor Gpr119-Induced Activation of Gastrointestinal Mucosal ResponsesCell Metabolism, 2010
- TGR5-Mediated Bile Acid Sensing Controls Glucose HomeostasisCell Metabolism, 2009
- Glucose Sensing in L Cells: A Primary Cell StudyCell Metabolism, 2008
- Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participantsOsteoporosis International, 2008
- Coding of Sweet, Bitter, and Umami TastesCell, 2003